Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MuSK-CAART in anti-MuSK antibody positive myasthenia gravis
NCT05451212Phase 1Completed
- Sponsor
- Cabaletta Bio
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MuSK-CAART in myasthenia gravis (MG) (2 cohorts), sponsored by Cabaletta Bio. Primary endpoint: Adverse Events at 3 months. Started Nov 2022; status: completed.
02
Drugs
MuSK-CAART
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05451212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451212.